Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MNOV presentation. My guess is the current run was partly fueled by this:
http://www.wallstreetscope.com/morning-buzz-nvidia-corporation-nasdaqnvda-medicinova-inc-nasdaqmnov-motorola-solutions-nysemsi-net-element-international-inc-nasdaqnete-innophos-holdings-inc-nasdaqiphs/2528627/
MediciNova, Inc. (NASDAQ:MNOV) announced that it has been invited to present data on MN-001 (tipelukast). It will present the data at the 65th Annual Meeting of the American Association event that focuses on the study of liver diseases. The event will take place in Boston and run from November 7 – 11. MNOV will present during the late-breaking poster session. Return on Investment for MediciNova Inc. (NASDAQ:MNOV) is -15.70% and on Tuesday its shares closed at $3.39. MediciNova Inc. (NASDAQ:MNOV) monthly performance stands at 38.93% while its year to date performance is 58.41%.
Yes, the cameraman was in much stronger condition and I hope he recovers, whether thru the drug or the excellent care he is getting. That said, he is only the second human to try the drug for Ebola. I am still not sure how this is going to come out for him.
I do have confidence in the drug, especially against Adenovirus.
Right now, with Duncan having died, I would expect most traders to bail and the stock to return to somewhere in the mid 20s. For long-term investors, I would expect the company to be acquired by a larger player by the end of 2015 in the mid or upper 40s. Good time to accumulate if you are patient.
I believe the issue is more that CMRX is not sure of the MOA of how their drug would affect the Ebola virus. The drug works very well on Adenovirus and has been safely used by more than 1000 ill to very ill patients.
Duncan was just too far gone.
de rien.
I have to confess I also took the opportunity to trim my position in MNOV at $3.75 this morning. It could come back to bite me, but it's an IRA account, so no tax consequences. Still holding 75 percent of my position (in case we have a rocket) and expect to add the 25 percent back if it dips back down toward $3.
Karin, Thanks for the article. Kroll often has some great insights in the life sciences and explains things well. Steve
Harm, Thanks! Steve
This was the primary intended use for CMRX drug candidate.
http://seekingalpha.com/pr/11255465-chimerixs-brincidofovir-shows-potential-survival-benefit-in-adenovirus-infection?app=n
Chimerix's Brincidofovir Shows Potential Survival Benefit in Adenovirus Infection
Wed October 8, 2014 6:30 AM|GlobeNewswire | About: CMRX
DURHAM, N.C., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. These data will be presented at the annual meeting of the Infectious Diseases Society of America (IDSA), IDWeek, on Saturday, October 11 at 10:50 a.m. EDT in Philadelphia, PA.
The preliminary survival analysis data, based on 48 evaluable patients from the ongoing AdVise Trial, showed a mortality rate of 35 percent compared with the historic rates of up to 80 percent mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus, an infection that can progress rapidly in patients with a weakened immune system due to disease or medications.
"When progressive adenovirus infection occurs in immunocompromised patients, they deteriorate, and the infection can be fatal in up to four of every five cases," said Dr. Jo-Anne Young, Professor of Medicine and Medical Director of the Program in Transplant Infectious Disease at the University of Minnesota. "In these very sick patients who were treated with brincidofovir, nearly two-thirds of the patients survived the first few weeks when we have historically seen the highest mortality. These results are encouraging and warrant the continued evaluation of brincidofovir as a promising antiviral for this life-threatening infection, for which a treatment is desperately needed."
Chimerix (CMRX) initiated AdVise in March 2014 based on potency observed in vitro and on clinical data from a Phase 2 trial and a large expanded access trial which showed the potential for improved clinical outcomes. As of September 19th, 48 subjects had enrolled in AdVise, with 35 percent mortality observed to date (17 of 48) with a median duration of observation of 57 days for living patients.
The trial is enrolling pediatric and adult patients with adenovirus infection who receive brincidofovir twice weekly for twelve weeks. Baseline information and at least two months of follow up are available for 26 subjects. Of those 26 patients, 23 had measurable viral loads at study entry, and three patients had no virus detectable in the blood but had diagnosed adenovirus infection. Fourteen of the 23 patients with viremia at study entry achieved undetectable viral loads during treatment. Twelve of the 26 patients died.
Over half of the subjects were hematopoeitic cell transplant (HCT) recipients with disseminated disease, but solid organ transplant recipients and patients undergoing chemotherapy were also enrolled. Over one-third of the subjects (10 of 26) had a second active infection with another DNA virus in addition to adenovirus, including BK virus (27 percent), cytomegalovirus (19 percent) and Epstein Barr virus (8 percent).
The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events. Of the six subjects who enrolled in the study with adenovirus-related diarrhea, three reported improvement of symptoms and three remained stable.
"These data reinforce the potential for brincidofovir to significantly impact the mortality from adenovirus infections and provide data to support the design of the pivotal trial," said W. Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix. "It is also important that, particularly in patients who are struggling with adenovirus infection, more than one-third of patients have more than one DNA virus, which underscores the need for a safe and broad-spectrum antiviral."
About AdVise
AdVise is a Phase 3 clinical trial to evaluate the safety and efficacy of brincidofovir for the treatment of adenovirus infection. In March 2014, Chimerix initiated the open-label pilot portion of the study. Chimerix is working closely with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 study that will be a continuation of this pilot study. Adenovirus infection can be associated with a mortality rate of up to 80 percent in patients who are undergoing hematopoeitic cell transplants (HCT), and there are no therapies approved to treat this infection. Adenovirus causes upper respiratory infections, including the common cold in individuals with a functional immune system, but it can lead to graft failure, severe pneumonia, hepatitis or death in those with a weakened immune system, such as patients who have undergone a transplant.
About Brincidofovir (BCV, CMX001)
Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenovirus. Brincidofovir has not been associated with kidney or bone marrow toxicity in nearly 900 patients treated to date, side effects that can be treatment limiting with currently available antivirals. Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial. Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.
Chimerix anti-viral shows potential survival benefit • 8:05 AM
Douglas W. House, SA News Ed...
Chimerix's (NASDAQ:CMRX) lead product candidate, brincidofovir, demonstrated a reduction on mortality rate from 80% to 35% in 48 evaluable patients in a Phase 3 trial assessing the safety and efficacy of brincidofovir as a treatment for patients with adenovirus infection. There are no FDA-approved therapies for this infection which has a historic mortality rate of up to 80%.
The company will present the data this Saturday at the annual meeting of the Infectious Diseases Society of America in Philadelphia.
Separately, clinicians have given brincidofovir to the two Ebola-stricken patients in the U.S., Thomas Eric Duncan in Texas and Ashoka Mukpo in Nebraska. Mr. Duncan's condition has improved. His temperature and blood pressure are back to normal but he remains on a ventilator and is receiving kidney dialysis.
At some point, MARA will do one of their acquisitions of a patent portfolio for stock. That will be another possible point at which the float may start to increase as the seller may sell some shares.
duplicate message
And price in Japan appears to be down 5 percent.
Harm,
Aren't the rules for most late-breaking poster sessions that there has to be some NEW data to release? If so, I'm looking forward to those data.
Steve
Fun,
Very well said. Bravo.
Steve
Okaly,
That's a reasonable approach for you, and you seem to know what you are doing with charting. I am definitely not the TA type; mostly just FA.
Where I take exception with your approach was back a few months when you seemed to be bashing the stock and trying to talk down the price. While it is unlikely that comments on IHub will have much effect on the overall market for ROX, and seasoned investors won't pay much attention, it can have much more effect on neophyte investors.
Just IMHO,
Steve (into ROX at 0.28)
Maposh,
Okaly trades in and out of ROX. That type of trading is not for everyone.
If you are a beginning investor, study your stock well before you buy. If you like your stock, hold it and wait for your investment to at least achieve a long-term capital gain.
Steve
LCRG,
One reason, at least today, might be the emergency approval of a drug from CMR* today by the FDA as a treatment for Ebola. It is also more or less available now and was administered to the Liberian guy being treated in Texas. This is the same drug administered to that kid Josh, where the adenovirus was interfering with his transplant.
Disclosure: I am long both HEB and the other stock.
Steve
$3.34 on US markets as I write this.
You can look on Yahoo finance, Seeking Alpha, Bloomberg and many other financial sites. I generally have daily or "as it happens" notices sent from Google, RTT and Seeking Alpha on each of my stocks. While some of the coverage is going to be rote, machine-generated pap (such and such stock "surged" .04 percent yesterday), you also get some timely gems.
The nature of the coverage you get on news will let you decide which free services you want to continue with and which ones are just garbage to which you can try to unsubscribe.
BTW, you don't want to follow advice from "the street." Don't set a stop-loss order on your shares either.
No, but if we get a form 4 we'll know it's Phil Frost. No form 4, probably a whale/institutional investor.
Hope they all (beekeepers and bees) prosper!
Not buzzing so much here in my suburban neighborhood. By my house I mostly see bumblebees, carpenter bees, wasps and hornets. A friend does keep a working hive.
Bees in Central PA do what differently from bees here near DC?
Harm, I like the rising price action in Tokyo much better than the dropping price here. Steve
Regarding Ebola I presume? They did not pin down a date in their 9/24/14 PR, only saying:
"In the collaboration Inovio and GeneOne will co-develop Inovio's DNA-based Ebola vaccine through a phase I clinical trial. The companies are currently conducting pre-IND activities and plan to start the clinical study in the first half of 2015."
Karin, Thank you. Actually.here.since.04/13. Just.don't.post.much. Steve EOM
I would not be surprised if Dr. Frost has in mind to combine both of his "sin" stocks at some point, just as he has done with life sciences entities in the past.
Overview.of.MediciNova's.Clinical.Trial.of.MN-166.(ibudilast).in.ALS to be Presented at The 13th Annual NEALS Meeting
Published: Sept 29, 2014 7:00 p.m. ET
Time (EDT)MediciNova Inc.10:0011:0012:001:002:003:004:00
$2.70$2.75$2.80$2.85$2.90$2.95$3.00
LA JOLLA, Calif., Sep 29, 2014 (GLOBE NEWSWIRE via COMTEX) --
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV, +3.15% and the JASDAQ Market of the Tokyo Stock Exchange (code number:4875), today announced that principal investigator Benjamin Rix Brooks, MD, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute in Charlotte, NC, will present an overview of MediciNova's clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at The 13th Annual NEALS Meeting to be held October 22 - 24, 2014 in Clearwater Beach, Florida. NEALS is the Northeast Amyotrophic Lateral Sclerosis Consortium.
The presentation "A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) – STEP-IBUDILAST-ALS-DB-OLE-1" will explain the rationale and study design for MediciNova's clinical trial.
About the ALS Trial
This is a single center, randomized, double-blind, placebo-controlled, 6-month study designed to evaluate the safety, tolerability and clinical endpoint responsiveness of MN-166 (60 mg/day) when administered as an adjunct to riluzole (100 mg/day) in subjects with amyotrophic lateral sclerosis (ALS). This study consists of two treatment arms, MN-166 and matching placebo, and randomization will occur in a 2:1 ratio (mn-166:placebo). To be eligible, subjects must have a diagnosis of sporadic or familial ALS with onset of less than 3 years from first clinical weakness prior to screening and must be on a stable dose of riluzole for at least 1 month prior to study drug treatment. A total of approximately 60 male and female subjects from 18 to 80 years old, inclusive will be enrolled (40 subjects in the MN-166 group; 20 subjects in the placebo group).
Upon completion of the Double-blind Phase, subjects randomized to the placebo arm will continue for an additional 6 months and will receive open-label MN-166. If there are no safety or tolerability concerns in the MN-166 treated group, a decision will be made to extend participation to the MN-166 treated group into the Open-Label Extension (OLE) Phase. Otherwise, only the placebo-treated patients will participate in the OLE Phase.
The primary objective is to evaluate the safety and tolerability of MN-166 60 mg/day versus placebo when administered for 6 months with riluzole in subjects with ALS. The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/day versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by the following assessments:
Functional activity as assessed by the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R)
Respiratory function as measured by slow vital capacity (SVC), Maximum Inspiratory Pressure (MIP) also known as Negative Inspiratory Force (NIF) and Forced Expiratory Volume in 1 second (FEV1) measured under SVC protocol
Muscle strength measured by manual muscle testing (MMT) and instrumented hand grip dynamometry
Non-invasive ventilation (NIV) utilization measured by clinically indicated prescription for NIV intervention and time to clinically indicated prescription for NIV intervention in each group
Steven Pearlstein and Allan Sloane are among my favorite writers on general finance. Calm, level-headed, open your eyes with clear succinct explanations.
Update on MN-166 progress:
http://finance.yahoo.com/news/medicinova-provides-phase-2b-trial-230000740.html
MediciNova Provides Update on Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
MediciNova, Inc. 2 hours ago GlobeNewswire
LA JOLLA, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that, as of September 15, 2014, the ongoing Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS) had enrolled 150 of the 250 subjects planned to be enrolled. Enrollment is expected to be completed during the first quarter of 2015.
The study is being funded by the U.S. National Institutes of Health (NIH) and is being conducted by the NeuroNEXT clinical trial network within the National Institute of Neurological Disorders and Stroke (NINDS) at the NIH. The collaboration to perform the study includes 28 academic medical centers, MediciNova and advocacy support from the National Multiple Sclerosis Society. The principal investigator is Robert Fox, M.D., M.S., FAAN, Vice-Chair for Research, Neurological Institute, Cleveland Clinic.
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to have completed 60% of the enrollment in this study. We look forward to providing further updates as the study progresses."
About the Progressive MS Trial
The Phase 2 Secondary and Primary Progressive Ibudilast NeuroNEXT trial in Multiple Sclerosis (SPRINT-MS) involves 28 enrolling clinical sites across the U.S. and is designed to evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) administered twice daily to subjects with primary or secondary progressive multiple sclerosis (PPMS or SPMS, respectively). 250 qualifying subjects will be randomly assigned 1:1 to inactive control (placebo) or MN-166 (ibudilast) administered at a dose of 100 mg/day (i.e., 50 mg twice daily). The progressive MS subjects may be either untreated with long-term disease modifying therapy (DMT) or may continue either glatiramer acetate (GA) or interferon beta (IFNß-1a or IFNß-1b) treatment. Hence, randomization will be controlled (stratified) by two factors: therapy status (IFN/GA vs. no DMT) and disease status (PPMS vs. SPMS). The primary objectives of the study are 1) to evaluate the activity of ibudilast (MN-166) versus placebo at 96 weeks as measured by quantitative magnetic resonance imaging (MRI) analysis for whole brain atrophy using brain parenchymal fraction (BPF), and 2) to evaluate the safety and tolerability of ibudilast (MN-166) (100 mg/day) versus placebo administered orally in subjects with primary or secondary progressive multiple sclerosis. Secondary measures include disability, imaging analyses of brain and retinal tissue integrity, cortical atrophy, cognitive impairment, quality-of-life, and neuropathic pain. Exploratory objectives include pharmacokinetic and biomarker analyses.
About the Cooperative Effort
The collaborating entities include NeuroNEXT, the Cleveland Clinic, the National MS Society and MediciNova. NINDS's Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. NeuroNEXT sites include many of the leading medical centers in the U.S. The goals of NeuroNEXT include testing of promising neurological therapies in Phase 2 clinical trials, optimizing drug development time and cost components through an established clinical trials infrastructure, and the coordination of public/private sector efforts by leveraging NINDS' existing relationships with academic investigators and patient advocacy groups. A clinical coordinating center for the network is based at Massachusetts General Hospital and the data coordinating center is at University of Iowa. Dr. Fox and colleagues at the Cleveland Clinic collaborate with co-investigators at academic medical centers in the NeuroNEXT network. The National MS Society is providing patient advocate input and trial enrollment awareness. MediciNova holds the trial IND with the FDA Division of Neurology Products and additionally provides scientific and analytical support and drug and placebo supply.
About Progressive Multiple Sclerosis
According to the National MS Society, MS affects approximately 2.1 million people worldwide. Approximately 85% of MS patients are initially diagnosed with relapsing remitting MS (RRMS). Approximately 50% of RRMS patients transition into secondary progressive MS (SPMS) in which there are fewer or no relapses but gradual worsening of health. Approximately 10% of MS patients are diagnosed with primary progressive MS (PPMS) at onset and exhibit increasing disabilities in walking, vision, mental acuity, and other bodily functions that are typical in both PPMS and SPMS without ever experiencing relapses or remissions. Current therapies for multiple sclerosis (MS) affect the inflammatory response, but provide limited benefit for neurodegeneration and/or brain tissue repair. There is an unmet need for agents which may provide neuroprotection. A National MS Society multi-disciplinary focus group has described some of the key features of each type of MS as follows:
George,
I can't PM you back, being a free member. Just look at post 219, where the first link was a filing by TEVA that it owned 9.6% of the BLRX shares. I think that is link enough!
You could send me your email, so we can talk offline.
Steve
And further:
http://www.nasdaq.com/markets/ipos/company/biolinerx-ltd-837767-65260
there was an attempted IPO in 2010, which was withdrawn 9/24/2010.
So, perhaps TEVA does have IMHO a right of first refusal to buy or license promising programs developed by BLRX.
Going a bit deeper, I found:
http://secfilings.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingConvPDF1?ID=8404009&SessionID=NN086nA74DS6nbo
As of 2/14/12 but effective as of 12/31/11, TEVA reported Sole Voting Power over 1,188,953 American Depositary Receipts, representing 9.6% ownership, and that this represents 10x this number in underlying shares
I also saw on linkedin: https://www.linkedin.com/pub/abi-vainstein-haras/25/bb6/a4b
Abi Vainstein-Haras
Medical Director at BioLineRx
Israel
Pharmaceuticals
Current
BioLineRx,
Teva Pharmaceutical Industries Ltd.
Previous
Teva Pharmaceuticals,
Meir Hospital,
Shaare Zedek Medical Center
Education
University of Buenos Aires
And, formerly: https://www.linkedin.com/in/danielalbahari
Daniel Albahari M.Sc., RAC
Regulatory Affairs - Drugs and Medical device
Israel
Biotechnology
Current
Voyant HEALTH (Brainlab Company)
Previous
N. Danenberg Holding Ltd,
BiolineRx,
Abic Biologic Laboratories Teva Ltd
Education
The Hebrew University
However, given TEVA's size, I would expect there to be many ex-TEVA folks at almost all Israeli biotech firms.
George,
Sorry it took me so long to get to it but I see only limited connection with TEVA via the Chairman of the Board. I would be happy to have my impression corrected. Note: I did not do a deep dive.
What I see is that trading began with ADRs (here in the US) in September 2011 at $5/share. There were also ADSs issued in May 2014, although these may have subsumed what were earlier referred to as ADRs.
Among the managers I also see no mention of TEVA:
http://www.biolinerx.com/default.asp?pageid=32
"Our Management
BioLineRx’s management team brings together seasoned executives with decades of experience in medicine, drug development, clinical studies, and financial and corporate development.
KINNERET SAVITSKY, PhD (Chief Executive Officer)
Dr. Savitsky assumed her current position as Chief Executive Officer in January 2010. Previously, from 2004 through 2010, Dr. Savitsky served as the general manager of BioLine Innovations Jerusalem. Prior to joining BioLineRx, Dr. Savitsky served as the Vice President of Biology at Compugen Ltd. (NASDAQ: CGEN). Dr. Savitsky completed her Ph.D. at Tel Aviv University. Dr. Savitsky also holds a B.Sc. in Biology from the Hebrew University of Jerusalem and a Masters degree in Human Genetics from Tel Aviv University.
PHILIP A. SERLIN, CPA, MBA (Chief Financial & Operating Officer)
Mr. Serlin assumed his position as Chief Financial & Operating Officer in May 2009. Prior to joining BioLineRx, Mr. Serlin was Chief Financial Officer and Chief Operating Officer of Kayote Networks Ltd. Mr. Serlin also served as Chief Financial Officer of Tescom Software Systems Testing Ltd. (TASE:TSCM), an IT services company publicly traded in both Tel Aviv and London. His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. accounting department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters. Mr. Serlin is a CPA and holds a Master’s degree in Economics and Public Policy from The George Washington University.
LEAH KLAPPER, PhD (Chief Scientific Officer)
Dr. Klapper was appointed Chief Scientific Officer of BioLineRx in December 2013. Prior to that, she served as General Manager at BioLine Innovations Jerusalem from 2010 through 2013, and before that as Vice President of Pre-clinical development from 2004 through 2010. Before joining BioLineRx, Dr. Klapper served as Vice President of Research and Development at CureTech Ltd., a biotechnology company developing novel immune-modulating molecules, where she founded the research and development laboratories and led the company from the bench to clinical studies. Dr. Klapper gained extensive post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle Washington. Dr. Klapper holds a PhD in Immunology and Cancer Research from the Weizmann Institute of Science. In addition, she holds an MSc in Pharmacology from the Department of Pharmacology at Tel Aviv University and a BSc in Life Sciences from Tel Aviv University.
DAVID MALEK, MBA (Vice President of Business Development)
David Malek was appointed as Vice President of Business Development in October 2011. Prior to joining BioLineRx, since 2006, Mr. Malek served at Sanofi in a number of management positions in the US and France, including Marketing, Finance and Business Development. Most recently Mr. Malek served as Director of Oncology - New Products and Business Development. Mr. Malek has an MBA from the Tuck Business School at Dartmouth College and also holds a BA in Statistics and Political Science from the University of Haifa.
ARNON AHARON, MD (Vice President of Medical Affairs)
Dr. Aharon was appointed Vice President of Medical Affairs as of January 2014. Prior to joining BioLineRx, Dr. Aharon served as Clinical Director, Medical Director or VP of Development at several biotechnology companies, the most recent being Thrombotech Ltd. and LycoRed Ltd. In addition, Dr. Aharon has been a partner in R&D Integrative Solutions, a firm that provides consulting services to the biotechnology industry and academic centers. Dr. Aharon holds a B.Sc in Medical Sciences and an M.D. from Tel Aviv University."
Closest I see is the Board Chairman, who is ex-TEVA
"AHARON SCHWARTZ, PhD, Chairman
Dr. Aharon Schwartz has been serving as Chairman of BioLineRx’s BOD since 2003. Dr. Schwartz retired after 36 years from Teva Pharmaceutical Industries where his recent position was Vice President Innovative Ventures. Previously at Teva, he served as Vice President of the Copaxone Division, Vice President of Business Development/Export Division and Head of the Pharmaceutical Division. Dr. Schwartz serves as Chairman of BioCancell Ltd. (TASE:BICL), D-Pharm Ltd. (TASE: DPRM), Amorphical Ltd. and Yissum Research and Development Company of the Hebrew University of Jerusalem. He also serves as member of the boards of numerous life science companies, including Clal Biotechnology Industries Ltd. (TASE: CBI). Dr. Schwartz received his Ph.D. in organic chemistry from the Weizmann Institute, his M.Sc. in organic chemistry from the Technion Institute of Technology, and a B.Sc. in chemistry and physics from the Hebrew University."
In regard to ownership, I would have expected a TEVA stake, but instead found: https://finance.yahoo.com/q/mh?s=BLRX+Major+Holders
Sorry about the formatting.
Major Holders Get Major Holders for:
Breakdown
% of Shares Held by All Insider and 5% Owners: NaN
% of Shares Held by Institutional & Mutual Fund Owners: NaN
% of Float Held by Institutional & Mutual Fund Owners: NaN
Number of Institutions Holding Shares:
MAJOR DIRECT HOLDERS (FORMS 3 & 4)
Holder Shares Reported
No Major Direct Holder info Available for BLRX
Top Institutional Holders
Holder Shares % Out Value* Reported
Sabby Management, LLC 2,021,347 5.93 4,204,401 Jun 30, 2014
Rima Senvest Management LLC 1,591,367 4.66 3,310,043 Jun 30, 2014
BVF Inc. 1,501,000 4.40 3,122,080 Jun 30, 2014
Orbimed Advisors LLC. 1,135,000 3.33 2,360,800 Jun 30, 2014
Opaleye Management Inc. 650,000 1.91 1,352,000 Jun 30, 2014
Sphera Funds Management Ltd 600,000 1.76 1,248,000 Jun 30, 2014
Deutsche Bank Aktiengesellschaft 191,850 0.56 399,048 Jun 30, 2014
Perceptive Advisors LLC 165,698 0.49 344,651 Jun 30, 2014
Renaissance Technologies, LLC 43,700 0.13 90,896 Jun 30, 2014
Benchmark Capital Advisors 40,000 0.12 83,200 Jun 30, 2014
Regarding our earlier conversation about them being broader that just stem cells, their pipeline (from their site) is:
"BioLineRx’s pipeline currently consists of six clinical stage therapeutic candidates:
BL-1040, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients which was out-licensed to Bellerophon Therapeutics (f/k/a Ikaria), (pivotal CE Mark registration trial);
BL-8040, for acute myeloid leukemia (AML) and other hematological cancers (Phase II);
BL-7010, a novel, non-absorbable, high molecular weight polymer intended for the treatment of celiac disease (Phase I);
BL-5010, a novel formulation for non-surgical removal of skin lesions (Phase I/II clinical trial completed);
BL-7040, a novel, orally available synthetic oligonucleotide for the treatment of inflammatory bowel disease (Phase II);
BL-8020, an orally available interferon-free treatment for Hepatitis C (HCV) and other viral indications (Phase I/II).
Additional compounds are currently in the pipeline at various stages of pre-clinical development for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases."
Regards,
Steve
Ah, too many analysts whose firms receive compensation in one way or another from the companies they write about. Such an incestuous industry. Note I am saying that in general, not about particular analysts.
George,
Yes, in biotech you have to be prepared to sit patiently for years until the initial premise works it's successful way thru all the different stages of research. No biotechs for you!
Seriously, you have to look at the science, assess what you can of the competition, buy your lottery tickets, BLRX included, and watch carefully to make sure they have the cash to pull it off. Then you have to hope whoever is the Chair of the Fed does not pronounce your sector overpriced, that AF doesn't start target practice on your stock and that Henry Waxman does not pronounce your drug/device/treatment unconsionably overpriced.
I can see why many folks use biotechs to trade in and out of.
Steve
George, I have had some of my stocks (e.g. TSRX, PBTH) bought out, but I'd like to think I was not chasing just the prospect of a buyout. Perhaps the acquirers saw what I did but also knew how to profit from it. I think BLRX has a number of promising programs and I prefer not to think of it as just a "stem cell company." Steve
Maybe Funman can travel to distant beverage outlets and proselytize for carrying ROX products.
We will see if they respond and the tenor of the response.
There is a site - intended for determining whether a hotel review is an "honest" one - which I use for lots of things. I'll run the response thru that. Just FYI, since I know you'll ask, it is:
http://beta.reviewskeptic.com/
Fun, Received acknowledgement from Playboy/no response yet. Steve
Playboy
To Me
Today at 12:55 PM
Dear Steve:
We are forwarding your inquiry to the appropriate department for handling.
If you should need further assistance, please be sure to include all previous e-mail correspondence.
Thank you for subscribing to Playboy Magazine.
Sincerely,
Marcy